JP6334166B2 - Ｆａｂグリコシル化抗体 - Google Patents

Ｆａｂグリコシル化抗体 Download PDF

Info

Publication number
JP6334166B2
JP6334166B2 JP2013523612A JP2013523612A JP6334166B2 JP 6334166 B2 JP6334166 B2 JP 6334166B2 JP 2013523612 A JP2013523612 A JP 2013523612A JP 2013523612 A JP2013523612 A JP 2013523612A JP 6334166 B2 JP6334166 B2 JP 6334166B2
Authority
JP
Japan
Prior art keywords
antibody
derivative
fragment
amino acid
fab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013523612A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013535970A5 (enExample
JP2013535970A (ja
Inventor
シュテフェン ゴレッツ，
シュテフェン ゴレッツ，
アンチェ ダニエルチク，
アンチェ ダニエルチク，
ラルス ステックル，
ラルス ステックル，
Original Assignee
グリコトープ ゲーエムベーハー
グリコトープ ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グリコトープ ゲーエムベーハー, グリコトープ ゲーエムベーハー filed Critical グリコトープ ゲーエムベーハー
Publication of JP2013535970A publication Critical patent/JP2013535970A/ja
Publication of JP2013535970A5 publication Critical patent/JP2013535970A5/ja
Application granted granted Critical
Publication of JP6334166B2 publication Critical patent/JP6334166B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2013523612A 2010-08-10 2011-08-10 Ｆａｂグリコシル化抗体 Active JP6334166B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2010/004878 2010-08-10
EP2010004878 2010-08-10
PCT/EP2011/063791 WO2012020065A1 (en) 2010-08-10 2011-08-10 Fab-glycosylated antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016149616A Division JP2016185169A (ja) 2010-08-10 2016-07-29 Ｆａｂグリコシル化抗体

Publications (3)

Publication Number Publication Date
JP2013535970A JP2013535970A (ja) 2013-09-19
JP2013535970A5 JP2013535970A5 (enExample) 2014-09-25
JP6334166B2 true JP6334166B2 (ja) 2018-05-30

Family

ID=44674756

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013523612A Active JP6334166B2 (ja) 2010-08-10 2011-08-10 Ｆａｂグリコシル化抗体
JP2016149616A Withdrawn JP2016185169A (ja) 2010-08-10 2016-07-29 Ｆａｂグリコシル化抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016149616A Withdrawn JP2016185169A (ja) 2010-08-10 2016-07-29 Ｆａｂグリコシル化抗体

Country Status (12)

Country Link
US (1) US9359439B2 (enExample)
EP (1) EP2603528B1 (enExample)
JP (2) JP6334166B2 (enExample)
CN (1) CN103119064B (enExample)
AU (1) AU2011288464B2 (enExample)
BR (1) BR112013003095B1 (enExample)
CA (1) CA2805984C (enExample)
DK (1) DK2603528T3 (enExample)
ES (1) ES2605304T3 (enExample)
PL (1) PL2603528T3 (enExample)
PT (1) PT2603528T (enExample)
WO (1) WO2012020065A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9051370B2 (en) 2010-08-10 2015-06-09 Glycotope Gmbh Humanized EGFR antibodies
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
KR102420934B1 (ko) 2013-03-11 2022-07-15 젠자임 코포레이션 과글리코실화된 결합 폴리펩티드
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
CN105229030A (zh) * 2013-04-22 2016-01-06 葛莱高托普有限公司 用具有低岩藻糖基化的抗-egfr抗体的抗-癌治疗
EP4640239A2 (en) 2014-03-19 2025-10-29 Genzyme Corporation Site-specific glycoengineering of targeting moieties
CN114181312A (zh) * 2014-09-10 2022-03-15 豪夫迈·罗氏有限公司 半乳糖改造的免疫球蛋白1抗体
CA2944085C (en) * 2014-09-16 2018-04-10 Ease Charm Limited Anti-egfr antibody and uses of same
PL3204425T3 (pl) 2014-10-09 2021-03-08 Genzyme Corporation Glikomodyfikowane koniugaty przeciwciał z lekami
EP3271391A1 (en) * 2015-03-20 2018-01-24 Ablynx N.V. Glycosylated immunoglobulin single variable domains
WO2017162733A1 (en) * 2016-03-22 2017-09-28 Glycotope Gmbh Iga antibodies with enhanced stability
CA3050039A1 (en) * 2017-01-27 2018-08-02 Glycotope Gmbh Anti-cancer treatments with an anti-muc1 antibody and an erbb inhibitor
CN110352074B (zh) 2017-02-28 2024-07-16 思进股份有限公司 用于偶联的半胱氨酸突变抗体
EP3707167A4 (en) * 2017-11-09 2021-08-04 National Research Council of Canada ANTIBODY GLYCOCONJUGATES, PRODUCTION AND USE PROCESSES
BR112020023373A2 (pt) 2018-05-18 2021-02-09 Daiichi Sankyo Company, Limited conjugado, composição, e, uso de um conjugado ou de uma composição
EP3947458A1 (en) 2019-04-03 2022-02-09 Genzyme Corporation Anti-alpha beta tcr binding polypeptides with reduced fragmentation
CA3196014A1 (en) * 2020-09-21 2022-03-24 Systimmune, Inc. Specificity enchanced bispecific antibody (seba)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
GB9200415D0 (en) 1992-01-09 1992-02-26 Bagshawe Kenneth D Inactivation of cytotoxic drugs
US5443953A (en) * 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
AU6267896A (en) 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
US6172213B1 (en) * 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US20040192898A1 (en) 2001-08-17 2004-09-30 Jia Audrey Yunhua Anti-abeta antibodies
WO2003074679A2 (en) 2002-03-01 2003-09-12 Xencor Antibody optimization
DE10303664A1 (de) 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
EP1706079B1 (en) * 2003-08-14 2013-02-20 ThromboGenics N.V. Antibodies against factor viii with modified glycosylation in the variable region
WO2005017130A2 (en) 2003-08-18 2005-02-24 Glycotope Gmbh Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses thereof
JP4913604B2 (ja) 2004-02-13 2012-04-11 グリコトープ ゲーエムベーハー 高活性糖タンパク質−製造条件、及びその効率的製造方法
US20060051353A1 (en) * 2004-05-14 2006-03-09 Jean-Frederic Colombel Methods and compositions to evaluate antibody treatment response
CA2607663C (en) 2005-05-19 2014-08-12 Amgen Inc. Compositions and methods for increasing the stability of antibodies
WO2007005786A2 (en) 2005-06-30 2007-01-11 Centocor, Inc. Methods and compositions with enhanced therapeutic activity
GB0519398D0 (en) * 2005-09-23 2005-11-02 Antisoma Plc Biological materials and uses thereof
CA2631630A1 (en) * 2005-11-30 2007-06-07 University Of Southern California Fc.gamma. polymorphisms for predicting disease and treatment outcome
HRP20150307T1 (hr) * 2006-09-10 2015-04-24 Glycotope Gmbh Upotreba ljudskih stanica podrijetlom iz ljudske leukemije za eksprimiranje protutijela
WO2008101177A2 (en) 2007-02-16 2008-08-21 University Of Virginia Patent Foundation Ige antibodies to chimeric or humanized igg therapeutic monoclonal antibodies as a screening test for anaphylaxis
CA2720610C (en) * 2008-04-07 2016-08-23 Bayer Healthcare Llc Methods of recombinant production of glycoproteins
AU2009256246B2 (en) * 2008-06-03 2013-07-18 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
US9051370B2 (en) * 2010-08-10 2015-06-09 Glycotope Gmbh Humanized EGFR antibodies

Also Published As

Publication number Publication date
AU2011288464A1 (en) 2013-02-14
CN103119064A (zh) 2013-05-22
BR112013003095A2 (pt) 2016-07-05
PT2603528T (pt) 2016-12-01
DK2603528T3 (en) 2016-11-28
US20130209458A1 (en) 2013-08-15
ES2605304T3 (es) 2017-03-13
WO2012020065A1 (en) 2012-02-16
JP2016185169A (ja) 2016-10-27
US9359439B2 (en) 2016-06-07
AU2011288464B2 (en) 2015-10-29
EP2603528B1 (en) 2016-10-12
EP2603528A1 (en) 2013-06-19
CA2805984A1 (en) 2012-02-16
BR112013003095B1 (pt) 2023-03-28
JP2013535970A (ja) 2013-09-19
CA2805984C (en) 2021-05-25
CN103119064B (zh) 2018-09-04
PL2603528T3 (pl) 2017-07-31

Similar Documents

Publication Publication Date Title
JP6334166B2 (ja) Ｆａｂグリコシル化抗体
JP7390414B2 (ja) 糖類工学による部位特異的抗体－薬物コンジュゲーション
TW202003583A (zh) 抗ｍｕｃ１抗體
JP2017507953A (ja) 抗ｃｄ３８抗体との併用療法
KR20150054931A (ko) 변경된 당화 및 감소된 효과기 기능을 갖는 fc 함유 폴리펩티드
CN119569881B (zh) 抗cd39抗体及其用途
RU2804703C2 (ru) Конъюгат антитело против muc1-лекарственное средство
RU2831409C2 (ru) Сайт-специфическая конъюгация антитело-лекарственное средство посредством гликоинженерии
HK40090526A (zh) 组合疗法
HK1213271B (en) Hyperglycosylated binding polypeptides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140808

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140808

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20151124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160729

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160805

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20161007

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170721

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171128

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180426

R150 Certificate of patent or registration of utility model

Ref document number: 6334166

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250